Almas MSc - Kodiak Sciences Senior Operations
| KOD Stock | USD 6.67 0.12 1.83% |
Executive
Almas MSc is Senior Operations of Kodiak Sciences
| Address | 1200 Page Mill Road, Palo Alto, CA, United States, 94304 |
| Phone | 650 281 0850 |
| Web | https://kodiak.com |
Kodiak Sciences Management Efficiency
The company has Return on Asset of (0.2672) % which means that on every $100 spent on assets, it lost $0.2672. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.715) %, meaning that it generated no profit with money invested by stockholders. Kodiak Sciences' management efficiency ratios could be used to measure how well Kodiak Sciences manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.57. The current year's Return On Capital Employed is expected to grow to -0.6. At present, Kodiak Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 78.3 M, whereas Non Currrent Assets Other are forecasted to decline to about 8.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Debra SPHR | Mustang Bio | N/A | |
| Caroline Dupont | Biomea Fusion | N/A | |
| Richard Colonno | Assembly Biosciences | 74 | |
| Chau MBA | CytomX Therapeutics | N/A | |
| Mark Underwood | Madrigal Pharmaceuticals | N/A | |
| Lisa Nolan | Gossamer Bio | 62 | |
| Alan Freidman | Transcode Therapeutics | N/A | |
| Daniel MD | Transcode Therapeutics | 72 | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Matt Cravets | Gossamer Bio | N/A | |
| Robyn Hunter | Fortress Biotech Pref | 61 | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Dallan Murray | Sarepta Therapeutics | N/A | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| Mary Jenkins | Sarepta Therapeutics | N/A | |
| Robert Smith | Gossamer Bio | 55 | |
| RN MBA | Transcode Therapeutics | N/A | |
| Thorsten Kirschberg | Biomea Fusion | 54 | |
| Ronald Filippo | Madrigal Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.27 |
Kodiak Sciences Leadership Team
Elected by the shareholders, the Kodiak Sciences' board of directors comprises two types of representatives: Kodiak Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kodiak. The board's role is to monitor Kodiak Sciences' management team and ensure that shareholders' interests are well served. Kodiak Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kodiak Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Almas MSc, Senior Operations | ||
| Victor MD, Chairman, CoFounder | ||
| Michael Louie, Senior Officer | ||
| CPA MBA, CFO VP | ||
| Tracy Chien, VP Controller | ||
| Pablo MD, Senior Development | ||
| Stephen Raillard, Senior Manufacturing | ||
| Hong Liang, Senior Vice President - Discovery Medicine | ||
| MD MPH, Chief Officer |
Kodiak Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kodiak Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 226.57 M | ||||
| Shares Outstanding | 52.62 M | ||||
| Shares Owned By Insiders | 5.65 % | ||||
| Shares Owned By Institutions | 77.79 % | ||||
| Number Of Shares Shorted | 1.35 M | ||||
| Price To Earning | (2.29) X | ||||
| Price To Book | 1.89 X | ||||
| EBITDA | (259.02 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kodiak Sciences is a strong investment it is important to analyze Kodiak Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Kodiak Sciences' future performance. For an informed investment choice regarding Kodiak Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kodiak Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Kodiak Stock refer to our How to Trade Kodiak Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kodiak Sciences. If investors know Kodiak will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kodiak Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.64) | Return On Assets (0.27) | Return On Equity (0.71) |
The market value of Kodiak Sciences is measured differently than its book value, which is the value of Kodiak that is recorded on the company's balance sheet. Investors also form their own opinion of Kodiak Sciences' value that differs from its market value or its book value, called intrinsic value, which is Kodiak Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kodiak Sciences' market value can be influenced by many factors that don't directly affect Kodiak Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kodiak Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kodiak Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kodiak Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.